Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspective: combined forces.

× No keyword cloud information.

6 in total

1. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors: David Marin; Amr R Ibrahim; Claire Lucas; Gareth Gerrard; Lihui Wang; Richard M Szydlo; Richard E Clark; Jane F Apperley; Dragana Milojkovic; Marco Bua; Jiri Pavlu; Christos Paliompeis; Alistair Reid; Katayoun Rezvani; John M Goldman; Letizia Foroni
Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544

2. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors: François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal: Lancet Oncol Date: 2010-10-19 Impact factor: 41.316

3. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors:
Journal: Blood Date: 2013-04-25 Impact factor: 22.113

4. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors: Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal: Cancer Cell Date: 2002-08 Impact factor: 31.743

5. Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors: Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal: N Engl J Med Date: 2012-11-29 Impact factor: 91.245

6. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808

6 in total

5 in total

1. Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

Authors: Brett M Noel; Steven B Ouellette; Laura Marholz; Deborah Dickey; Connor Navis; Tzu-Yi Yang; Vinh Nguyen; Sarah J Parker; David Bernlohr; Zohar Sachs; Laurie L Parker
Journal: J Proteome Res Date: 2019-02-21 Impact factor: 4.466

Review 2. Targeting the LKB1 tumor suppressor.

Authors: Rui-Xun Zhao; Zhi-Xiang Xu
Journal: Curr Drug Targets Date: 2014-01 Impact factor: 3.465

Review 3. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.

Authors: David D Chism; Dinuka De Silva; Young E Whang
Journal: Expert Rev Anticancer Ther Date: 2014-06-13 Impact factor: 4.512

4. Pragmatic medicine in solid cancer: a translational alternative to precision medicine.

Authors: Jan Brábek; Daniel Rosel; Michael Fernandes
Journal: Onco Targets Ther Date: 2016-04-05 Impact factor: 4.147

5. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.

Authors: Ravi S Narayan; Piet Molenaar; Jian Teng; Fleur M G Cornelissen; Irene Roelofs; Renee Menezes; Rogier Dik; Tonny Lagerweij; Yoran Broersma; Naomi Petersen; Jhon Alexander Marin Soto; Eelke Brands; Philip van Kuiken; Maria C Lecca; Kristiaan J Lenos; Sjors G J G In 't Veld; Wessel van Wieringen; Frederick F Lang; Erik Sulman; Roel Verhaak; Brigitta G Baumert; Lucas J A Stalpers; Louis Vermeulen; Colin Watts; David Bailey; Ben J Slotman; Rogier Versteeg; David Noske; Peter Sminia; Bakhos A Tannous; Tom Wurdinger; Jan Koster; Bart A Westerman
Journal: Nat Commun Date: 2020-06-10 Impact factor: 14.919

5 in total